Provides Incremental Reimbursement in Hospital Outpatient Setting SANTA CLARA, Calif., June 11, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS) granted approval for a Transitional Pass-Through (TPT) payment for […]
Other News
Circle Cardiovascular Imaging Announces Partnership with DiA Imaging Analysis to Deliver All-in-One Comprehensive AI-Based Cardiovascular Imaging Solutions
CALGARY, Canada, and BE’ER SHEVA, Israel, June 14, 2021 /PRNewswire/ — Today, Circle Cardiovascular Imaging Inc. and DiA Imaging Analysis Ltd. are excited to announce a multi-year partnership that leverages the companies’ synergies in cardiac AI and data analytics. As a global leader in cardiovascular imaging reading and reporting for Cardiac MR and […]
CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting
PARIS–(BUSINESS WIRE)–CorWave, a French medical device company committed to the fight against heart failure, announced that it has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD) operating synchronously with the native heart without the use of sensors. The results were presented at the […]
GENinCode Announces Major US Commercialisation Partnership With EVERSANA
OXFORD, England, June 14, 2021 /PRNewswire/ — GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA”) as its launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused […]
CathWorks Announces Appointment of Ramin Mousavi as Chief Executive Officer and Board Member
KFAR-SABA, Israel and ALISO VIEJO, Calif., June 14, 2021 /PRNewswire/ — CathWorks, a global leader of digital health innovation focused on helping patients with cardiovascular disease, today announced that Ramin Mousavi has been appointed Chief Executive Officer, effective June 21, 2021. Mr. Mousavi has also been appointed to the company’s Board of Directors. Mr. Mousavi succeeds Jim Corbett, who […]
ERT Improves Patient Compliance in Cardiac Studies with Home Blood Pressure Service
Remote blood pressure monitoring service standardizes BP collection PHILADELPHIA, June 14, 2021 /PRNewswire/ — ERT, the global leader in clinical endpoint data collection, today announced the expansion of its clinical trial endpoint data collection portfolio with at-home blood pressure (BP) monitoring solution. This completes a suite of blood pressure assessment services developed by […]
BioCardia to Be Added to the Russell Microcap® Index
SAN CARLOS, Calif., June 14, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, today announced it is to join the Russell Microcap® Index. This milestone will take place at the conclusion of the 2021 Russell Indexes annual reconstitution, […]
Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the appointment of Steven Schoch to the Company’s Board of Directors and as Chair of the Audit Committee. Mr. Schoch brings more than 20 years of financial and operational leadership and expertise across a range of areas in biopharmaceuticals, media, and […]
Neovasc Provides Corporate Update
VANCOUVER and MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, […]
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
– Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response – BORDENTOWN, N.J. & BOSTON–(BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in patients with AL […]



